Abivax S.A.(ABVX)Earnings, Financials & Key Ratios
ABVX•NASDAQ
Price updated Jun 11, 2026
AboutABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.Show more
- Revenue$0
- EBITDA-$245M-42.5%
- Net Income-$336M-90.7%
- EPS (Diluted)-4.65-66.1%
- ROE-135.64%+9.0%
- Debt/Equity0.07-97.1%
- Interest Coverage-10.60+19.6%
ABVX Key Insights
Abivax S.A. (ABVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 55.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 10.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 13.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ABVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABVX Price & Volume
Abivax S.A. (ABVX) stock price & volume — 10-year historical chart
Loading chart...
ABVX Growth Metrics
Abivax S.A. (ABVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-96.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.57%
Return on Capital
10 Years-72.3%
5 Years-93.12%
3 Years-91%
Last Year-77.68%
ABVX Recent Earnings
Abivax S.A. (ABVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 22, 2026EPS
$0.71
Est $0.94
+23.9%
Revenue
$2M
Est $401,125
+277.3%
Q2 2026
Mar 23, 2026EPS
$1.22
Est $1.07
-14.1%
Revenue
$515,064
Est $2M
-71.4%
Q4 2025
Sep 8, 2025EPS
$0.86
Est $0.90
+4.4%
Revenue
$2M
Est $1M
+70.6%
Q2 2025
Mar 24, 2025EPS
$1.55
Est $0.68
-128.0%
Revenue
$8M
Est $3M
+146.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 22, 2026 | $0.71vs $0.94+23.9% | $2Mvs $401,125+277.3% |
| Q2 2026 | Mar 23, 2026 | $1.22vs $1.07-14.1% | $515,064vs $2M-71.4% |
| Q4 2025 | Sep 8, 2025 | $0.86vs $0.90+4.4% | $2Mvs $1M+70.6% |
| Q2 2025 | Mar 24, 2025 | $1.55vs $0.68-128.0% | $8Mvs $3M+146.2% |
Based on last 12 quarters of dataView full earnings history →
ABVX Peer Comparison
Abivax S.A. (ABVX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARRY | 1.15B | 7.45 | -10.21 | 40.22% | -5.56% | -20.64% | 2.94 | |
 PTGX | 7.06B | 109.79 | -53.56 | -89.41% | -6.48% | -17.76% | 0.02 | |
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ARDX | 1.42B | 5.79 | -22.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCKT | 290.45M | 2.66 | -1.32 | -70.79% | 0.09 | |||
 ABBV | 397.56B | 224.77 | 94.84 | 8.57% | 6.91% | 62.15% | ||
 JNJ | 574.35B | 238.33 | 41.16 | 4.3% | 27.26% | 31.69% | 0.51 | |
 LLY | 1.1T | 1160.95 | 50.59 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare ABVX vs Peers
Abivax S.A. (ABVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABVX Income Statement
Abivax S.A. (ABVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 10K | 18K | 2K | 63K | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -92.13% | 80% | -88.89% | 3050% | -100% | - | - | - | - |
Cost of Goods Sold | 14.51M | 15.38M | 28.19M | 33.78M | 45.52M | 50.76M | 0 | 0 | 0 |
COGS % of Revenue | 145070% | 85427.78% | 1409400% | 53623.81% | - | - | - | - | - |
Gross Profit | -14.5M▲ 0% | -15.36M▼ 5.9% | -28.19M▼ 83.5% | -33.78M▼ 19.9% | -45.52M▼ 34.7% | -50.76M▼ 11.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | -144970% | -85327.78% | -1409300% | -53623.81% | - | - | - | - | - |
Gross Profit Growth % | 0.14% | -5.95% | -83.51% | -19.86% | -34.73% | -11.53% | 100% | - | - |
Operating Expenses | -347K | 3.75M | 5.11M | 4.23M | -4.12M | 14.07M | 127.38M | 172.98M | 246.06M |
OpEx % of Revenue | -3470% | 20827.78% | 255500% | 6707.94% | - | - | - | - | - |
Selling, General & Admin | 3.78M | 4.3M | 4.89M | 5.6M | 5.58M | 7.49M | 28.82M | 38.9M | 72.86M |
SG&A % of Revenue | 37820% | 23877.78% | 244600% | 8888.89% | - | - | - | - | - |
Research & Development | 0 | 0 | 0 | 0 | 47.78M | 48.3M | 103.18M | 146.53M | 177.76M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | -4.13M | -549K | 218K | -1.37M | -57.48M | -41.72M | -4.62M | -12.45M | -4.57M |
Operating Income | -14.15M▲ 0% | -19.11M▼ 35.0% | -33.3M▼ 74.3% | -38.01M▼ 14.2% | -41.4M▼ 8.9% | -64.84M▼ 56.6% | -127.38M▼ 96.5% | -172.98M▼ 35.8% | -246.06M▼ 42.2% |
Operating Margin % | -141500% | -106155.56% | -1664800% | -60330.16% | - | - | - | - | - |
Operating Income Growth % | 22.41% | -35.04% | -74.25% | -14.15% | -8.92% | -56.61% | -96.46% | -35.81% | -42.24% |
EBITDA | -14.06M | -19.04M | -33.22M | -37.94M | -41.1M | -64.35M | -126.67M | -171.88M | -244.98M |
EBITDA Margin % | -140570% | -105761.11% | -1660800% | -60225.4% | - | - | - | - | - |
EBITDA Growth % | 23.06% | -35.43% | -74.48% | -14.23% | -8.32% | -56.58% | -96.84% | -35.7% | -42.53% |
D&A (Non-Cash Add-back) | 93K | 71K | 80K | 66K | 302K | 485K | 707K | 1.1M | 1.07M |
EBIT | -14.07M | -19.33M | -33.3M | -38.06M | -38.89M | -53.8M | -133.91M | -163.81M | -301.77M |
Net Interest Income | 116K | -460K | -1.67M | -2.32M | -3.56M | -6.94M | -11.05M | -3.48M | -22.73M |
Interest Income | 116K | 79K | 14K | 0 | 0 | 0 | 2.77M | 8.96M | 5.75M |
Interest Expense | 0 | 469K | 1.59M | 2.06M | 3.56M | 6.94M | 13.83M | 12.43M | 28.48M |
Other Income/Expense | 77K | -687K | -1.59M | -40.13M | -1.05M | 4.1M | -20.36M | -3.26M | -84.2M |
Pretax Income | -14.07M▲ 0% | -19.8M▼ 40.7% | -34.89M▼ 76.2% | -40.13M▼ 15.0% | -42.45M▼ 5.8% | -60.74M▼ 43.1% | -147.74M▼ 143.2% | -176.24M▼ 19.3% | -330.25M▼ 87.4% |
Pretax Margin % | -140730% | -109972.22% | -1744400% | -63693.65% | - | - | - | - | - |
Income Tax | -2.69M | -3.97M | -4.26M | -2.58M | 0 | 0 | 0 | 0 | 5.85M |
Effective Tax Rate % | 19.13% | 20.06% | 12.2% | 6.42% | 0% | 0% | 0% | 0% | -1.77% |
Net Income | -11.22M▲ 0% | -15.82M▼ 41.0% | -30.63M▼ 93.6% | -37.55M▼ 22.6% | -42.45M▼ 13.1% | -60.74M▼ 43.1% | -147.74M▼ 143.2% | -176.24M▼ 19.3% | -336.1M▼ 90.7% |
Net Margin % | -112230% | -87905.56% | -1531700% | -59604.76% | - | - | - | - | - |
Net Income Growth % | 21.56% | -40.99% | -93.6% | -22.58% | -13.05% | -43.08% | -143.23% | -19.29% | -90.7% |
Net Income (Continuing) | -11.38M | -15.82M | -30.63M | -37.55M | -42.45M | -60.74M | -147.74M | -176.24M | -336.1M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.13▲ 0% | -1.55▼ 37.2% | -2.51▼ 61.9% | -2.62▼ 4.4% | -2.75▼ 5.0% | -3.18▼ 15.6% | -3.43▼ 7.9% | -2.80▲ 18.4% | -4.65▼ 66.1% |
EPS Growth % | 23.13% | -37.17% | -61.94% | -4.38% | -4.96% | -15.64% | -7.86% | 18.37% | -66.07% |
EPS (Basic) | -1.14 | -1.56 | -2.51 | -2.62 | -2.75 | -3.18 | -3.43 | -2.80 | -4.65 |
Diluted Shares Outstanding | 9.93M | 10.21M | 12.18M | 14.31M | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
Basic Shares Outstanding | 9.87M | 10.18M | 12.18M | 14.31M | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ABVX Balance Sheet
Abivax S.A. (ABVX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 20.88M | 20.98M | 18.24M | 37.67M | 75.21M | 36.18M | 285.97M | 170.67M | 551.01M |
Cash & Short-Term Investments | 17.03M | 13M | 9.77M | 29.3M | 60.7M | 26.95M | 260.99M | 144.22M | 530.16M |
Cash Only | 1.88M | 8M | 9.77M | 29.3M | 60.7M | 26.95M | 251.94M | 144.22M | 516.47M |
Short-Term Investments | 15.15M | 5.01M | 6K | 6K | 6K | 0 | 9.05M | 0 | 13.69M |
Accounts Receivable | 3.65M | 7.77M | 6.98M | 8.04M | 8.34M | 8.32M | 19.1M | 15.66M | 10.49M |
Days Sales Outstanding | 133.12K | 157.62K | 1000K | 46.58K | - | - | - | - | - |
Inventory | 199K | 0 | 1.15M | 0 | 4M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 5.01 | - | 14.92 | - | 32.08 | - | - | - | - |
Other Current Assets | 198K | 1K | 0 | 1K | 0 | 0 | -1K | 0 | 0 |
Total Non-Current Assets | 32.94M | 33.07M | 33.48M | 33.63M | 35.15M | 39.36M | 41.09M | 34.56M | 33.08M |
Property, Plant & Equipment | 201K | 151K | 134K | 100K | 93K | 1.59M | 877K | 2.67M | 2.09M |
Fixed Asset Turnover | 0.05x | 0.12x | 0.01x | 0.63x | - | - | - | - | - |
Goodwill | 32.01M | 32.01M | 32.01M | 32.01M | 32.74M | 18.42M | 18.42M | 18.42M | 18.41M |
Intangible Assets | 0 | 0 | 85K | 98K | -647K | 6.61M | 6.6M | 6.61M | 6.6M |
Long-Term Investments | -14.42M | -4.09M | 221K | 215K | 214K | 0 | 124K | 126K | 0 |
Other Non-Current Assets | 2K | 5.01M | 1K | 1.21M | 2.75M | 12.74M | 15.07M | 6.74M | 5.98M |
Total Assets | 53.81M▲ 0% | 54.05M▲ 0.4% | 51.73M▼ 4.3% | 71.3M▲ 37.8% | 109.23M▲ 53.2% | 75.54M▼ 30.8% | 327.06M▲ 332.9% | 205.23M▼ 37.3% | 584.09M▲ 184.6% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - | - |
Asset Growth % | -11.19% | 0.43% | -4.29% | 37.83% | 53.2% | -30.84% | 332.94% | -37.25% | 184.61% |
Total Current Liabilities | 5.44M | 8.49M | 12.39M | 19.41M | 32.26M | 51.46M | 88.11M | 92.83M | 62.99M |
Accounts Payable | 4.22M | 6.65M | 10.54M | 17.41M | 18.56M | 15.47M | 47.22M | 43.82M | 0 |
Days Payables Outstanding | 106.15 | 157.94 | 136.54 | 188.08 | 148.82 | 111.27 | - | - | - |
Short-Term Debt | 0 | 10.9M | 20.74M | 12K | 10.06M | 29.49M | 30.88M | 42.84M | 1.3M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 162K | 133K | 52K | 0 | 0 |
Other Current Liabilities | 4K | -10.9M | -20.74M | 0 | -385K | 2.87M | 3.51M | 532K | 56.88M |
Current Ratio | 3.84x | 2.47x | 1.47x | 1.94x | 2.33x | 0.70x | 3.25x | 1.84x | 8.75x |
Quick Ratio | 3.80x | 2.47x | 1.38x | 1.94x | 2.21x | 0.70x | 3.25x | 1.84x | 8.75x |
Cash Conversion Cycle | 133.01K | - | 1000K | - | - | - | - | - | - |
Total Non-Current Liabilities | 196K | 10.9M | 20.74M | 33.99M | 51.03M | 16.89M | 42.94M | 71.81M | 66.09M |
Long-Term Debt | 0 | 10.9M | 20.74M | 33.98M | 40.27M | 8.29M | 26.62M | 52.16M | 30.22M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 43K | 839K | 160K | 1.43M | 553.76K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.85M |
Other Non-Current Liabilities | -4.07M | -5.91M | 5K | 9K | 10.37M | 7.76M | 16.15M | 18.22M | 29.46M |
Total Liabilities | 5.63M | 19.39M | 33.14M | 53.4M | 83.3M | 68.36M | 131.05M | 164.64M | 129.08M |
Total Debt | 0 | 10.9M | 20.74M | 33.99M | 51.65M | 39.16M | 58.04M | 97.36M | 32.08M |
Net Debt | -1.88M | 2.9M | 10.98M | 4.7M | -9.05M | 12.21M | -193.9M | -46.86M | -484.39M |
Debt / Equity | - | 0.31x | 1.12x | 1.90x | 1.99x | 5.45x | 0.30x | 2.40x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | - | -41.21x | -21.00x | -18.46x | -10.93x | -7.75x | -9.69x | -13.18x | -10.60x |
Total Equity | 48.18M▲ 0% | 34.66M▼ 28.1% | 18.59M▼ 46.4% | 17.9M▼ 3.7% | 25.93M▲ 44.9% | 7.19M▼ 72.3% | 196.01M▲ 2626.5% | 40.58M▼ 79.3% | 455.01M▲ 1021.2% |
Equity Growth % | -15.05% | -28.07% | -46.35% | -3.72% | 44.88% | -72.28% | 2626.53% | -79.29% | 1021.16% |
Book Value per Share | 4.85 | 3.39 | 1.53 | 1.25 | 1.68 | 0.38 | 4.55 | 0.64 | 6.54 |
Total Shareholders' Equity | 48.18M | 34.66M | 18.59M | 17.9M | 25.93M | 7.19M | 196.01M | 40.58M | 455.01M |
Common Stock | 99K | 102K | 122K | 143K | 168K | 223K | 629K | 633K | 784.66K |
Retained Earnings | -46.58M | -62.4M | -93.03M | -37.55M | -81.81M | -143.51M | -282.95M | -438.88M | -738.17M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 253K | 283K | 0 | -37.26M | 1K | 0 | 112K | -75K | 2.31M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABVX Cash Flow Statement
Abivax S.A. (ABVX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.45M | -14.6M | -27.47M | -29.82M | -45.66M | -53.94M | -100.01M | -154.07M | -155.69M |
Operating CF Margin % | -84490% | -81127.78% | -1373650% | -47338.1% | - | - | - | - | - |
Operating CF Growth % | 45.87% | -72.84% | -88.13% | -8.55% | -53.09% | -18.13% | -85.42% | -54.06% | -1.05% |
Net Income | -14.15M | -19.11M | -33.3M | -38.01M | -42.56M | -60.74M | -147.74M | -176.24M | -322.84M |
Depreciation & Amortization | 93K | 71K | 80K | 66K | 156K | 485K | 707K | 1.1M | 1.03M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 828K | -1.16M | 8.18M | 20.22M | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | -828K | 0 | 7.93M | 0 | 0 |
Other Non-Cash Items | 106K | -277K | -1.26M | -1.55M | -1.84M | 9.48M | 9.65M | -577K | 162.61M |
Working Capital Changes | 5.5M | 4.71M | 7.01M | 9.67M | -668K | -2M | 21.27M | 1.42M | 3.51M |
Change in Receivables | 724K | 12K | 3.14M | -3K | -1.98M | 312K | -14.23M | 4.59M | 6.76M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.65M | 2.44M | 0 | 0 | 1.14M | -2.39M | 31.76M | -3.44M | 0 |
Cash from Investing | -105K | -254K | -370K | -575K | -1.46M | -12.03M | -10.49M | 15.76M | -13.18M |
Capital Expenditures | -979K | -763K | -941K | -898K | -1.64M | -288K | -266K | -640K | -136.4K |
CapEx % of Revenue | 9790% | 4238.89% | 47050% | 1425.4% | - | - | - | - | - |
Acquisitions | 0 | 0 | 646K | 616K | 312K | -2.91M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 1.01M | 497K | -75K | 617K | 312K | -8.57M | -1.62M | 16.4M | 68.2K |
Cash from Financing | 2.6M | 10.83M | 24.61M | 49.93M | 78.51M | 32.21M | 340.57M | 28.21M | 531.94M |
Debt Issued (Net) | 2.06M | 10.18M | 10.95M | 23.53M | 19.13M | -9.71M | 15.24M | 37.49M | -56.31M |
Equity Issued (Net) | 628K | 652K | 13.67M | 26.39M | 69.68M | 46.37M | 353.39M | 434K | 588.84M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -85K | 0 | 0 | 0 | -10.3M | -4.45M | -28.06M | -9.71M | -586.89K |
Net Change in Cash | -5.96M▲ 0% | -4.03M▲ 32.3% | -3.23M▲ 19.8% | 19.53M▲ 704.5% | 31.4M▲ 60.8% | -33.75M▼ 207.5% | 224.99M▲ 766.6% | -107.72M▼ 147.9% | 389.36M▲ 461.5% |
Free Cash Flow | -9.43M▲ 0% | -15.37M▼ 63.0% | -28.41M▼ 84.9% | -30.72M▼ 8.1% | -47.3M▼ 54.0% | -54.26M▼ 14.7% | -100.28M▼ 84.8% | -154.72M▼ 54.3% | -155.83M▼ 0.7% |
FCF Margin % | -94280% | -85366.67% | -1420700% | -48763.49% | - | - | - | - | - |
FCF Growth % | 42.26% | -62.98% | -84.91% | -8.12% | -53.96% | -14.71% | -84.81% | -54.29% | -0.72% |
FCF per Share | -0.95 | -1.51 | -2.33 | -2.15 | -3.06 | -2.84 | -2.33 | -2.45 | -2.24 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.92x | 0.90x | 0.79x | 1.08x | 0.89x | 0.68x | 0.87x | 0.46x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABVX Key Ratios
Abivax S.A. (ABVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -22.27% | -21.4% | -38.2% | -115.06% | -205.8% | -193.7% | -366.77% | -145.41% | -148.98% | -135.64% |
| Return on Invested Capital (ROIC) | -28.47% | -22.25% | -34.18% | -74.4% | -109.29% | -157.26% | -267.98% | -888.17% | - | - |
| Gross Margin | -11431.5% | -144970% | -85327.78% | -1409300% | -53623.81% | - | - | - | - | - |
| Net Margin | -11266.14% | -112230% | -87905.56% | -1531700% | -59604.76% | - | - | - | - | - |
| Debt / Equity | 0.01x | - | 0.31x | 1.12x | 1.90x | 1.99x | 5.45x | 0.30x | 2.40x | 0.07x |
| Interest Coverage | -427.05x | - | -41.21x | -21.00x | -18.46x | -10.93x | -7.75x | -9.69x | -13.18x | -10.60x |
| FCF Conversion | 1.09x | 0.75x | 0.92x | 0.90x | 0.79x | 1.08x | 0.89x | 0.68x | 0.87x | 0.46x |
| Revenue Growth | 202.38% | -92.13% | 80% | -88.89% | 3050% | -100% | - | - | - | - |
Related:ABVX Dividend History·ABVX Revenue History·ABVX Price History·ABVX P/E History·ABVX Financial Ratios·ABVX Institutional Holders
ABVX Frequently Asked Questions
Abivax S.A. (ABVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Abivax S.A. (ABVX) grew revenue by 0.0% over the past year. Growth has been modest.
Abivax S.A. (ABVX) reported a net loss of $427.2M for fiscal year 2025.
Dividend & Returns
Abivax S.A. (ABVX) has a return on equity (ROE) of -135.6%. Negative ROE indicates the company is unprofitable.
Abivax S.A. (ABVX) had negative free cash flow of $250.0M in fiscal year 2025, likely due to heavy capital investments.